Loading...
Market
Story
Organon to Acquire Dermavant and VTAMA Cream in $175 Million APA Deal
Sep 18, 2024, 11:35 AM
Organon has announced its acquisition of Dermavant, including its innovative dermatologic therapy, VTAMA (tapinarof) Cream 1%. The deal includes an upfront payment of $175 million, with additional payments up to $1.2 billion based on sales milestones. An additional $75 million is contingent on VTAMA's approval in AtD. This acquisition, structured as an APA, highlights Organon's commitment to expanding its dermatology portfolio.
View original story
Similar markets
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than $100 million • 25%
$100 million to $199 million • 25%
$200 million to $299 million • 25%
$300 million or more • 25%
Less than $100 million • 25%
$100 million to $199 million • 25%
$200 million to $299 million • 25%
$300 million or more • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%